Recorded fact · drug.trial_access

drug.trial_access for apixaban

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 664a5c02 resolves to.

The record

Fact id	`664a5c02865dd35883930c69`
Entity	drug: apixaban
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "APIXABAN",
 "recruitingInterventionalCount": 61,
 "notYetRecruitingCount": 25,
 "byPhase": {
  "PHASE3": 18,
  "PHASE2": 4,
  "NA": 14,
  "PHASE4": 21,
  "PHASE1": 2,
  "EARLY_PHASE1": 2
 },
 "trials": [
  {
   "nctId": "NCT07015905",
   "briefTitle": "REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2025-06-25",
   "conditions": [
    "Venous Thromboembolism (VTE)"
   ],
   "countries": [
    "United States",
    "Bulgaria",
    "Hungary",
    "Japan",
    "Latvia",
    "Lithuania",
    "Poland",
    "Romania"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07015905"
  },
  {
   "nctId": "NCT07175428",
   "briefTitle": "Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2025-10-20",
   "conditions": [
    "Atrial Fibrillation (AF)"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Brazil",
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07175428"
  },
  {
   "nctId": "NCT07493304",
   "briefTitle": "Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-08-26",
   "conditions": [
    "Venous Thromboembolism (VTE)"
   ],
   "countries": [
    "United States",
    "Bulgaria",
    "Japan",
    "Romania",
    "South Korea"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07493304"
  },
  {
   "nctId": "NCT07626411",
   "briefTitle": "Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-08-10",
   "conditions": [
    "Atrial Fibrillation (AF)"
   ],
   "countries": [
    "United States",
    "Canada",
    "Japan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07626411"
  },
  {
   "nctId": "NCT07471139",
   "briefTitle": "SWITCH: Apixaban vs Vitamin K in HM3",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Columbia University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-10-15",
   "conditions": [
    "LVAD (Left Ventricular Assist Device) Thrombosis",
    "Heart Failure",
    "Bleeding"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07471139"
  },
  {
   "nctId": "NCT05701917",
   "briefTitle": "DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Inari Medical",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2023-01-06",
   "conditions": [
    "Venous Thromboembolism",
    "Deep Venous Thrombosis",
    "Post-Thrombotic Syndrome"
   ],
   "countries": [
    "United States",
    "Austria",
    "Finland",
    "Germany",
    "Switzerland",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05701917"
  },
  {
   "nctId": "NCT06401616",
   "briefTitle": "Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Odense University Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-21",
   "startDate": "2024-05-21",
   "conditions": [
    "Atrial Fibrillation",
    "Left Atrial Appendage Absent",
    "Anticoagulant Adverse Reaction"
   ],
   "countries": [
    "Denmark"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06401616"
  },
  {
   "nctId": "NCT07869615",
   "briefTitle": "Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Military Hospital of Tunis",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-16",
   "startDate": "2026-09-15",
   "conditions": [
    "Total Knee Arthroplasty",
    "Venous Thromboembolism"
   ],
   "countries": [
    "Tunisia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07869615"
  },
  {
   "nctId": "NCT07237308",
   "briefTitle": "BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Yonsei University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-16",
   "startDate": "2026-07-14",
   "conditions": [
    "Stroke",
    "Ischemic",
    "Atrial Fibrillation"
   ],
   "countries": [
    "South Korea"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07237308"
  },
  {
   "nctId": "NCT07840365",
   "briefTitle": "Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Texas Cardiac Arrhythmia Research Foundation",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-05",
   "startDate": "2026-09-01",
   "conditions": [
    "Atrial Fibrillation (AF)"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07840365"
  },
  {
   "nctId": "NCT04642430",
   "briefTitle": "COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Ottawa Hospital Research Institute",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-01",
   "startDate": "2021-07-06"
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 465ad42b1f1b48af66c8ab8cdbe236c3f07976610048eb917a88b14eb29705c5.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.